References
- Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (rendu-osler-weber syndrome). Am J Med Genet 2000; 91:66-67; PMID:10751092
- Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012 Mar 7; 307(9):948-55; PMID:22396517; http://dx.doi.org/10.1001/jama.2012.250
- Epperla N, Hocking W. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia. Clin Med Res 2014 Mar 25. [Epub ahead of print]; PMID:24667223
- Kanellopoulou T, Alexopoulou A. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia. Expert Opin Biol Ther 2013 Sep; 13(9):1315-23; Epub 2013 Jul 2; PMID:23815519; http://dx.doi.org/10.1517/14712598.2013.813478
- Cirulli A, Liso A, D'Ovidio F, Mestice A, Pasculli G, Gallitelli M, Rizzi R, Specchia G, Sabbà C. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol 2003; 110(1):29-32; PMID:12975554; http://dx.doi.org/10.1159/000072411
- Sadick H, Riedel F, Naim R, Goessler U, Hörmann K, Hafner M, Lux A. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005 Jun; 90(6):818-28; PMID:15951295
- Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EE, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, et al. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist 2013; 18(8):965-70; Epub 2013 Jul 30; PMID:23900000; http://dx.doi.org/10.1634/theoncologist.2013-0006
- Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, Yuan J, Hefner C, Chartier C, Lee JS, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006 Jul; 12(7):793-800; Epub 2006 Jun 25; PMID:16799557; http://dx.doi.org/10.1038/nm1428
- Kelly RJ, Rixe O. Axitinib - a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol 2009 Dec; 4(4):297-305; Epub 2009 Oct 30; PMID:19876699; http://dx.doi.org/10.1007/s11523-009-0126-9
- www.ema.europa.eu